Clinical Trial Update: Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adoptive cellular immunotherapy after autologous stem cell transplantation in multiple myeloma completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Myeloma, Transplant-eligible Patients | Phase 2 | Status: COMPLETED | Results posted: 2019-03-26